Neuro-ophthalmic challenges and multi-morbidity in vasculitis among the older adults

References

• Jennette JC, Falk RJ, Bacon PA, et al. 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheumatism. 2013 Jan 01;65(1):1–11. doi: 10.1002/art.37715
   PubMed Web of Science ®Google Scholar
• Dejaco C, Duftner C, Buttgereit F, et al. The spectrum of giant cell arteritis and polymyalgia rheumatica: revisiting the concept of the disease. Rheumatology (Oxford). 2017 Apr 1;56(4):506–515. doi: 10.1093/rheumatology/kew273
   PubMed Web of Science ®Google Scholar
• Watts RA, Hatemi G, Burns JC, et al. Global epidemiology of vasculitis. Nat Rev Rheumatol. 2022 Jan 01;18(1):22–34. doi: 10.1038/s41584-021-00718-8
   PubMed Web of Science ®Google Scholar
• Saadoun D, Vautier M, Cacoub P. Medium- and Large-Vessel Vasculitis. Circulation. 2021 Jan 19;143(3):267–282. doi: 10.1161/CIRCULATIONAHA.120.046657
   PubMed Web of Science ®Google Scholar
• Haynes BF, Kaiser-Kupfer MI, Mason P, et al. Cogan syndrome: studies in thirteen patients, long-term follow-up, and a review of the literature. Medicine (Baltimore). 1980 Nov;59(6):426–441.
   PubMed Web of Science ®Google Scholar
• Catanoso M, Macchioni P, Boiardi L, et al. Epidemiology of granulomatosis with polyangiitis (Wegener׳s granulomatosis) in Northern Italy: A 15-year population-based study. Semin Arthritis Rheum. 2014 Oct 01;44(2):202–207. doi: 10.1016/j.semarthrit.2014.05.005
   PubMed Web of Science ®Google Scholar
• Watts RA, Lane SE, Bentham G, et al. Epidemiology of systemic vasculitis: A ten-year study in the United Kingdom. Arthritis & Rheumatism. 2000 Feb 01;43(2):414. doi: 10.1002/1529-0131(200002)43:2<414:AID-ANR23>3.0.CO;2-0
   PubMed Web of Science ®Google Scholar
• Kitching AR, Anders HJ, Basu N, et al. ANCA-associated vasculitis. Nat Rev Dis Primers. 2020 Aug 27;6(1):71. doi: 10.1038/s41572-020-0204-y
   PubMed Web of Science ®Google Scholar
• Berti A, Caporali R, Montecucco C, et al. Aging in primary systemic vasculitis: implications for diagnosis, clinical manifestations, and management. Drugs Aging. 2019 Jan 01;36(1):53–63. doi: 10.1007/s40266-018-0617-4
   PubMed Web of Science ®Google Scholar
• Rutter M, Bowley J, Lanyon PC, et al. A systematic review and meta-analysis of the incidence rate of Takayasu arteritis. Rheumatology (Oxford). 2021 Nov 3;60(11):4982–4990. doi: 10.1093/rheumatology/keab406
   PubMed Web of Science ®Google Scholar
• Li KJ, Semenov D, Turk M, et al. A meta-analysis of the epidemiology of giant cell arteritis across time and space. Arthritis Res Ther. 2021 Mar 11;23(1):82. doi: 10.1186/s13075-021-02450-w
   PubMed Web of Science ®Google Scholar
• Berti A, Cornec D, Crowson CS, et al. The epidemiology of antineutrophil cytoplasmic autoantibody-associated vasculitis in olmsted county, Minnesota: a twenty-year US population-based study. Arthritis Rheumatol. 2017 Dec;69(12):2338–2350.
   PubMed Web of Science ®Google Scholar
• Li KJ, Semenov D, Turk M, et al. A meta-analysis of the epidemiology of giant cell arteritis across time and space. Arthritis Res Ther. 2021 Dec 01;23(1). doi: 10.1186/s13075-021-02450-w
   Web of Science ®Google Scholar
• Crowson CS, Matteson EL, Myasoedova E, et al. The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthritis & Rheumatism. 2011 Mar 01;63(3):633–639. doi: 10.1002/art.30155
   PubMed Web of Science ®Google Scholar
• González-Gay MÁ, Pina T, Prieto-Peña D, et al. Treatment of giant cell arteritis. Biochem Pharmacol. 2019 Jul 01;165:230–239.
   PubMed Web of Science ®Google Scholar
• Mohan SV, Liao YJ, Kim JW, et al. Giant cell arteritis: immune and vascular aging as disease risk factors. Arthritis Res Ther. 2011 Aug 2;13(4):231. doi: 10.1186/ar3358
   PubMed Web of Science ®Google Scholar
• Weyand CM, Ma-Krupa W, Goronzy JJ. Immunopathways in giant cell arteritis and polymyalgia rheumatica. Autoimmun Rev. 2004 Jan;3(1):46–53. doi: 10.1016/S1568-9972(03)00064-8
   PubMed Web of Science ®Google Scholar
• Samson M, Corbera-Bellalta M, Audia S, et al. Recent advances in our understanding of giant cell arteritis pathogenesis. Autoimmun Rev. 2017 Aug;16(8):833–844.
   PubMed Web of Science ®Google Scholar
• Hunder GG, Bloch DA, Michel BA, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis & Rheumatism. 1990 Aug 17;33(8):1122–1128. doi: 10.1002/art.1780330810
   PubMed Web of Science ®Google Scholar
• Vilaseca J, Gonzalez A, Cid MC, et al. Clinical usefulness of temporal artery biopsy. Ann Rheumatic Dis. 1987 Apr 01;46(4):282–285. doi: 10.1136/ard.46.4.282
   PubMed Web of Science ®Google Scholar
• Ponte C, Grayson PC, Robson JC, et al. 2022 American College of Rheumatology/EULAR classification criteria for giant cell arteritis. Arthritis Rheumatol. 2022 Dec 01;74(12):1881–1889. doi: 10.1002/art.42325
   PubMed Web of Science ®Google Scholar
• Vodopivec I, Rizzo JF III. Ophthalmic manifestations of giant cell arteritis. Rheumatology. 2018;57(suppl_2):ii63–ii72.
   PubMed Web of Science ®Google Scholar
• Chen JJ, Leavitt JA, Fang C, et al. Evaluating the incidence of arteritic ischemic optic neuropathy and other causes of vision loss from giant cell arteritis. Ophthalmol. 2016 Sep 01;123(9):1999–2003. doi: 10.1016/j.ophtha.2016.05.008
   PubMed Web of Science ®Google Scholar
• Blockmans D, Ceuninck LD, Vanderschueren S, et al. Repetitive18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: A prospective study of 35 patients. Arthritis & Rheumatism. 2006 Feb 15;55(1):131–137. doi: 10.1002/art.21699
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Barros S, Lopez-Diaz MJ, et al. Giant cell arteritis: disease patterns of clinical presentation in a series of 240 patients. Medicine. 2005;84(5):269–276. doi: 10.1097/01.md.0000180042.42156.d1
   PubMed Web of Science ®Google Scholar
• Hansen ME, Springer J, Byram K. Diagnostic and therapeutic challenges of vasculitis. Can J Cardiol. 2022 May 01;38(5):623–633. doi: 10.1016/j.cjca.2022.02.007
   PubMed Web of Science ®Google Scholar
• Castañeda S, Prieto-Peña D, Vicente-Rabaneda EF, et al. Advances in the treatment of giant cell arteritis. J Clin Med. 2022 Mar 13;11(6):1588. doi: 10.3390/jcm11061588
   PubMed Web of Science ®Google Scholar
• González-Gay M, Pina T, Prieto-Peña D, et al. Treatment of giant cell arteritis. Biochem Pharmacol. 2019 Jul;165:230–239. doi: 10.1016/j.bcp.2019.04.027
   PubMed Web of Science ®Google Scholar
• González-Gay MA, Blanco R, Rodríguez-Valverde V, et al. Permanent visual loss and cerebrovascular accidents in giant cell arteritis: Predictors and response to treatment. Arthritis & Rheumatism. 1998;41(8):1497–1504. doi: 10.1002/1529-0131(199808)41:8<1497:AID-ART22>3.0.CO;2-Z
   PubMed Web of Science ®Google Scholar
• González-Gay MA, Castañeda S, Llorca J. Giant cell arteritis: visual loss is our major concern. J Rheumatol. 2016;43(8):1458–1461. doi: 10.3899/jrheum.160466
   PubMed Web of Science ®Google Scholar
• Hellmich B, Agueda A, Monti S, et al. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2020 Jan 01;79(1):19–30. doi: 10.1136/annrheumdis-2019-215672
   PubMed Web of Science ®Google Scholar
• Dua AB, Husainat NM, Kalot MA, et al. Giant cell arteritis: a systematic review and meta‐analysis of test accuracy and benefits and harms of common treatments. ACR Open Rheumatol. 2021 Jul 01;3(7):429–441. doi: 10.1002/acr2.11226
   PubMedGoogle Scholar
• Jover JA, Hernández-García C, Morado IC, et al. Combined treatment of giant-cell arteritis with methotrexate and prednisone. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2001 Jan 16;134(2):106–114. doi: 10.7326/0003-4819-134-2-200101160-00010
   PubMed Web of Science ®Google Scholar
• Antonio AA, Santos RN, Abariga SA. Tocilizumab for giant cell arteritis. Cochrane Database Syst Rev. 2022 May 13;5(5):Cd013484.
   PubMedGoogle Scholar
• Oray M, Abu Samra K, Ebrahimiadib N, et al. Long-term side effects of glucocorticoids. Expert Opin Drug Saf. 2016 Apr 02;15(4):457–465. doi: 10.1517/14740338.2016.1140743
   PubMed Web of Science ®Google Scholar
• Atienza-Mateo B, Prieto-Peña D, Vicente-Rabaneda EF, et al. Utility of tocilizumab in autoimmune eye diseases. Expert Opin Biol Ther. 2022 Jun;22(6):789–799.
   PubMed Web of Science ®Google Scholar
• Howard SC, Mccormick J, Pui C-H, et al. Preventing and managing toxicities of high-dose methotrexate. Oncology. 2016 Dec 01;21(12):1471–1482. doi: 10.1634/theoncologist.2015-0164
   Google Scholar
• Caporali R, Crepaldi G, Codullo V, et al. 20 years of experience with tumour necrosis factor inhibitors: what have we learned? Rheumatology. 2018;57(Supplement_7):vii5–vii10. doi: 10.1093/rheumatology/key059
   PubMedGoogle Scholar
• Dasgupta B, Borg FA, Hassan N, et al. BSR and BHPR guidelines for the management of giant cell arteritis. Rheumatology (Oxford). 2010 Aug;49(8):1594–1597.
   PubMed Web of Science ®Google Scholar
• Hotchi M. Pathological studies on Takayasu arteritis. Heart Vessels Suppl. 1992;7(S1):11–17. doi: 10.1007/BF01744538
   PubMedGoogle Scholar
• Sanchez-Alvarez C, Crowson CS, Koster MJ, et al. Prevalence of Takayasu arteritis: a population-based study. J Rheumatol. 2021;48(6):952–952. doi: 10.3899/jrheum.201463. jrheum.201463.
   PubMed Web of Science ®Google Scholar
• Watts R, Al-Taiar A, Mooney J, et al. The epidemiology of Takayasu arteritis in the UK. Rheumatology (Oxford). 2009 Aug;48(8):1008–1011.
   PubMed Web of Science ®Google Scholar
• Hata A, Noda M, Moriwaki R, et al. Angiographic findings of Takayasu arteritis: new classification. Int J Cardiol. 1996 Aug;54 Suppl:S155–63. doi: 10.1016/S0167-5273(96)02813-6
   PubMed Web of Science ®Google Scholar
• Grayson PC, Maksimowicz-McKinnon K, Clark TM, et al. Distribution of arterial lesions in Takayasu’s arteritis and giant cell arteritis. Ann Rheum Dis. 2012 Aug;71(8):1329–1334.
   PubMed Web of Science ®Google Scholar
• Comarmond C, Biard L, Lambert M, et al. Long-term outcomes and prognostic factors of complications in Takayasu arteritis: a multicenter study of 318 patients. Circulation. 2017 Sep 19;136(12):1114–1122. doi: 10.1161/CIRCULATIONAHA.116.027094
   PubMed Web of Science ®Google Scholar
• Peter J, David S, Danda D, et al. Ocular manifestations of Takayasu arteritis: a cross-sectional study. Retina. 2011 Jun;31(6):1170–1178.
   PubMed Web of Science ®Google Scholar
• Hellmich B, Águeda AF, Monti S, et al. Treatment of giant cell arteritis and takayasu arteritis-current and future. Curr Rheumatol Rep. 2020 Oct 12;22(12):84. doi: 10.1007/s11926-020-00964-x
   PubMed Web of Science ®Google Scholar
• Nakaoka Y, Isobe M, Takei S, et al. Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study). Ann Rheum Dis. 2018 Mar;77(3):348–354.
   PubMed Web of Science ®Google Scholar
• Tombetti E, Mason JC. Takayasu arteritis: advanced understanding is leading to new horizons. Rheumatology. 2019;58(2):206–219. doi: 10.1093/rheumatology/key040
   PubMed Web of Science ®Google Scholar
• Keser G, Aksu K. What is new in management of Takayasu arteritis? Presse Méd. 2017 Jul 01;46(7, Part 2):e229–e235.
   PubMed Web of Science ®Google Scholar
• Pagnoux C, Seror R, Henegar C, et al. Clinical features and outcomes in 348 patients with polyarteritis nodosa: a systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French Vasculitis Study Group Database. Arthritis Rheum. 2010 Feb;62(2):616–626.
   PubMed Web of Science ®Google Scholar
• Mahr A, Guillevin L, Poissonnet M, et al. Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener’s granulomatosis, and Churg-Strauss syndrome in a French urban multiethnic population in 2000: a capture-recapture estimate. Arthritis Rheum. 2004 Feb 15;51(1):92–99. doi: 10.1002/art.20077
   PubMed Web of Science ®Google Scholar
• Watts RA, Lane SE, Bentham G, et al. Epidemiology of systemic vasculitis: a ten-year study in the United Kingdom. Arthritis Rheum. 2000 Feb;43(2):414–419.
   PubMed Web of Science ®Google Scholar
• Mohammad AJ, Jacobsson LT, Westman KW, et al. Incidence and survival rates in Wegener’s granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and polyarteritis nodosa. Rheumatology (Oxford). 2009 Dec;48(12):1560–1565.
   PubMed Web of Science ®Google Scholar
• de Boysson H, Guillevin L. Polyarteritis Nodosa Neurologic Manifestations. Neurol Clin. 2019 May;37(2):345–357. doi: 10.1016/j.ncl.2019.01.007
   PubMed Web of Science ®Google Scholar
• Hsu CT, Kerrison JB, Miller NR, et al. Choroidal infarction, anterior ischemic optic neuropathy, and central retinal artery occlusion from polyarteritis nodosa. Retina. 2001;21(4):348–351. doi: 10.1097/00006982-200108000-00009
   PubMed Web of Science ®Google Scholar
• Vingopoulos F, Karagiotis T, Palioura S. Bilateral interstitial keratitis, erythema nodosum and atrial fibrillation as presenting signs of polyarteritis nodosa. Am J Ophthalmol Case Rep. 2020 Jun;18:100619. doi: 10.1016/j.ajoc.2020.100619
   PubMedGoogle Scholar
• Provenzale JM, Allen NB. Neuroradiologic findings in polyarteritis nodosa. AJNR Am J Neuroradiol. 1996 Jun;17(6):1119–1126.
   PubMed Web of Science ®Google Scholar
• Bonitsis NG, Luong Nguyen LB, LaValley MP, et al. Gender-specific differences in Adamantiades–Behçet’s disease manifestations: an analysis of the German registry and meta-analysis of data from the literature. Rheumatology. 2015;54(1):121–133. doi: 10.1093/rheumatology/keu247
   PubMed Web of Science ®Google Scholar
• Yazici H, Tüzün Y, Pazarli H, et al. Influence of age of onset and patient’s sex on the prevalence and severity of manifestations of Behçet’s syndrome. Ann Rheum Dis. 1984 Dec;43(6):783–789. doi: 10.1136/ard.43.6.783
   PubMed Web of Science ®Google Scholar
• Espinoza GM, Wheeler J, Temprano KK, et al. Cogan’s syndrome: clinical presentations and update on treatment. Curr Allergy Asthma Rep. 2020 Jun 16;20(9):46. doi: 10.1007/s11882-020-00945-1
   PubMed Web of Science ®Google Scholar
• Gluth MB, Baratz KH, Matteson EL, et al. Cogan syndrome: a retrospective review of 60 patients throughout a half century. Mayo Clin Proc. 2006 Apr;81(4):483–488.
   PubMed Web of Science ®Google Scholar
• Vollertsen RS. Vasculitis and Cogan’s syndrome. Rheum Dis Clin North Am. 1990 May;16(2):433–439. doi: 10.1016/S0889-857X(21)01068-1
   PubMed Web of Science ®Google Scholar
• Orsoni JG, Zavota L, Pellistri I, et al. Cogan syndrome. Cornea. 2002 May;21(4):356–359.
   PubMed Web of Science ®Google Scholar
• Kessel A, Vadasz Z, Toubi E. Cogan syndrome–pathogenesis, clinical variants and treatment approaches. Autoimmun Rev. 2014 Apr;13(4–5):351–354. doi: 10.1016/j.autrev.2014.01.002
   PubMed Web of Science ®Google Scholar
• Kallenberg CGM. Pathophysiology of ANCA-Associated Small Vessel Vasculitis. Curr Rheumatol Rep. 2010 Dec 01;12(6):399–405.
   PubMedGoogle Scholar
• Sfiniadaki E, Tsiara I, Theodossiadis P, et al. Ocular manifestations of granulomatosis with polyangiitis: a review of the literature. Ophthalmol Ther. 2019 Jun 01;8(2):227–234. doi: 10.1007/s40123-019-0176-8
   PubMed Web of Science ®Google Scholar
• Ntatsaki E, Watts RA, Scott DG. Epidemiology of ANCA-associated vasculitis. Rheum Dis Clin North Am. 2010 Aug;36(3):447–461. doi: 10.1016/j.rdc.2010.04.002
   PubMed Web of Science ®Google Scholar
• De Groot K, Rasmussen N, Bacon PA, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis & Rheumatism. 2005 Aug 01;52(8):2461–2469. doi: 10.1002/art.21142
   PubMed Web of Science ®Google Scholar
• Pérez-Jacoiste Asín MA, Charles P, Rothschild P-R, et al. Ocular involvement in granulomatosis with polyangiitis: A single-center cohort study on 63 patients. Autoimmun Rev. 2019 May 01;18(5):493–500. doi: 10.1016/j.autrev.2019.03.001
   PubMed Web of Science ®Google Scholar
• Shih CB, Wang YC, Lai CC. Ocular and orbital exacerbation after rituximab therapy for granulomatosis with polyangiitis. Can J Ophthalmol. 2019 Oct;54(5):e237–e241. doi: 10.1016/j.jcjo.2018.12.004
   PubMed Web of Science ®Google Scholar
• Harigai M, Takada H. Avacopan, a selective C5a receptor antagonist, for anti-neutrophil cytoplasmic antibody-associated vasculitis. Mod Rheumatol. 2022 Apr 18;32(3):475–483.
   PubMed Web of Science ®Google Scholar
• Aggarwal P, Woolford SJ, Patel HP. Multi-morbidity and polypharmacy in older people: challenges and opportunities for clinical practice. Geriatrics. 2020;5(4):85.
   PubMed Web of Science ®Google Scholar
• Van Onna M, Boonen A. Challenges in the management of older patients with inflammatory rheumatic diseases. Nat Rev Rheumatol. 2022 Jun 01;18(6):326–334. doi: 10.1038/s41584-022-00768-6
   PubMed Web of Science ®Google Scholar
• Clegg A, Young J, Iliffe S, et al. Frailty in elderly people. Lancet. 2013 Mar 2;381(9868):752–762. doi: 10.1016/S0140-6736(12)62167-9
   PubMed Web of Science ®Google Scholar
• Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001 Mar;56(3):M146–56.
   PubMed Web of Science ®Google Scholar
• Cesari M, Gambassi G, van Kan GA, et al. The frailty phenotype and the frailty index: different instruments for different purposes. Age Ageing. 2014 Jan;43(1):10–12. doi: 10.1093/ageing/aft160
   PubMed Web of Science ®Google Scholar
• Kuchel GA. Frailty and resilience as outcome measures in clinical trials and geriatric care: are we getting any closer? J Am Geriatr Soc. 2018 Aug;66(8):1451–1454. doi: 10.1111/jgs.15441
   PubMed Web of Science ®Google Scholar
• Masnoon N, Shakib S, Kalisch-Ellett L, et al. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017 Dec 01;17(1). doi: 10.1186/s12877-017-0621-2
   PubMed Web of Science ®Google Scholar
• Camellino D, Matteson EL, Buttgereit F, et al. Monitoring and long-term management of giant cell arteritis and polymyalgia rheumatica. Nat Rev Rheumatol. 2020;16(9):481–495. doi: 10.1038/s41584-020-0458-5
   PubMed Web of Science ®Google Scholar
• Fein AS, Ko MW. Neuro-ophthalmologic complications of giant cell arteritis: diagnosis and treatment. Semin Neurol. 2019 Dec 01;39(6):673–681.
   PubMed Web of Science ®Google Scholar
• Robson JC, Kiran A, Maskell J, et al. The relative risk of aortic aneurysm in patients with giant cell arteritis compared with the general population of the UK. Ann Rheum Dis. 2015 Jan;74(1):129–135.
   PubMed Web of Science ®Google Scholar
• Chazal T, Lhote R, Rey G, et al. Giant-cell arteritis-related mortality in France: A multiple-cause-of-death analysis. Autoimmun Rev. 2018 Dec 01;17(12):1219–1224. doi: 10.1016/j.autrev.2018.06.012
   PubMed Web of Science ®Google Scholar
• Kermani TA, Sreih AG, Cuthbertson D, et al. Evaluation of damage in giant cell arteritis. Rheumatology (Oxford). 2018 Feb 1;57(2):322–328. doi: 10.1093/rheumatology/kex397
   PubMed Web of Science ®Google Scholar
• Park SJ, Kim HJ, Park H, et al. Incidence, prevalence, mortality and causes of death in Takayasu Arteritis in Korea - a nationwide, population-based study. Int J Cardiol. 2017 May 15;235:100–104.
   PubMed Web of Science ®Google Scholar
• Danesh-Meyer H, Savino PJ, Gamble GG. Poor prognosis of visual outcome after visual loss from giant cell arteritis. Ophthalmol. 2005 Jun;112(6):1098–1103. doi: 10.1016/j.ophtha.2005.01.036
   PubMed Web of Science ®Google Scholar
• Saripella A, Wasef S, Nagappa M, et al. Effects of comprehensive geriatric care models on postoperative outcomes in geriatric surgical patients: a systematic review and meta-analysis. BMC Anesthesiol. 2021 Apr 22;21(1):127. doi: 10.1186/s12871-021-01337-2
   PubMed Web of Science ®Google Scholar
• Ellis G, Gardner M, Tsiachristas A, et al. Comprehensive geriatric assessment for older adults admitted to hospital. Cochrane Database Syst Rev. 2017 Sep 12;9(9):Cd006211. doi: 10.1002/14651858.CD006211.pub3
   PubMed Web of Science ®Google Scholar
• Yosra C, Moez J, Chifa D, et al. Adverse events in long-term corticosteroid therapy in elderly: a case series of 71 patients. Int Med J. 2023;30(6):327–330.
   Google Scholar
• Kermani TA, Schäfer VS, Crowson CS, et al. Increase in age at onset of giant cell arteritis: a population-based study. Ann Rheum Dis. 2010 Apr;69(4):780–781.
   PubMed Web of Science ®Google Scholar
• Schmidt J, Smail A, Roche B, et al. Incidence of severe infections and infection-related mortality during the course of giant cell arteritis: a multicenter, prospective, double-cohort study. Arthritis Rheumatol. 2016 Jun;68(6):1477–1482.
   PubMed Web of Science ®Google Scholar
• Delaval L, Daumas A, Samson M, et al. Large-vessel vasculitis diagnosed between 50 and 60 years: Case-control study based on 183 cases and 183 controls aged over 60 years. Autoimmun Rev. 2019 Jul 01;18(7):714–720. doi: 10.1016/j.autrev.2019.05.008
   PubMed Web of Science ®Google Scholar
• Esen I, Arends S, Dalsgaard Nielsen B, et al. Metabolic features and glucocorticoid-induced comorbidities in patients with giant cell arteritis and polymyalgia rheumatica in a Dutch and Danish cohort. RMD Open. 2023;9(1):e002640. doi: 10.1136/rmdopen-2022-002640
   PubMed Web of Science ®Google Scholar
• Berti A, Felicetti M, Padoan R, et al., editors. FRI0310 Long-term mortality and complications in young and elderly patients with anca-associated vasculitis. Poster Presentations; 2017 June 14–17; Madrid, Spain. BMJ Publishing Group Ltd and European League Against Rheumatism; 2017 Jun 01.
   Google Scholar